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DIHYDROPYRIDINE CALCIUM-
CHANNEL BLOCKERS FOR 
ANTIHYPERTENSIVE TREATMENT 
IN OLDER PATIENTS - EVIDENCE 
FROM THE SYSTOLIC 
HYPERTENSION IN. EUROPE TRIAL 
Jan A Staessen, Lutgarde Thijs, Hilde Celis, Jerzy Gasowski, 
Ji G Wang, Robert H Fagard, for the Systolic Hypertension in 
Europe Trial Investigators (the Syst-Eur Trial) 
Objective. The Syst-Eur study investigated whether active 
antihypertensive treatment could reduce cardiovascular 
complications in elderly patients with isolated systolic 
hypertension. 
Design. Randomised, placebo-controlled, double-blind 
outcome trial. 
Setting. Hypertension clinics or genera.I practitioners' 
surgeries in 198 centres in 23 Western and Eastern European 
countries. 
Subjects. Patients aged :<:: 60 years with sitting systolic blood 
pressure (BP) 160 - 219 mmHg and sitting diastolic BP< 95 
mmHg during run-in phase. 
Methods and Results. Four thousand, six hundred and 
ninety-five patients were randomly assigned to active 
treatment (N = 2 398), i.e. nitrendipine, with the possible 
addition of enalapril and hydrochlorothiazide, or to 
matching placebos (N = 2 297). In the intentioncto-treat 
analysis, the between-group difference in blood pressure 
(BP) amounted to 10.1/4.5 mmHg (P < 0.001). Active 
treatment reduced the incidence of fatal and non-fatal 
stroke (primary endpoint) by 42% (P = 0.003). On active 
treatment all cardiac endpoints decreased by 26% (P = 0.03) 
and all cardiovascular endpoints by 31% (P < 0.001). 
Cardiovascular mortality was slightly lower on active 
treatment (-27%, P = 0.07), but all-cause mortality was not 
influenced (-14%, P = 0.22). For total (P = 0.009) and 
cardiovascular mortality (P = 0.09), the benefit of antihy-
pertensive treatment weakened with advancing age, and for 
total mortality it decreased with lower systolic BP at entry 
(P = 0.05). The benefits of active treatment were not 
independently related to sex or to the presence of 
cardiovascular complications at entry. The antihypertensive 
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regimen was more effective in patients with diabetes than in 
those without diabetes at entry. Further analyses also 
suggested benefit in patients who were taking nitrendipine 
as the sole therapy. The per-protocol analysis largely 
confirmed the intention-to-treat results. Active treatment 
reduced all strokes by 44% (P = 0.004), all cardiac endpoints 
by 26% (P = 0.05) and all cardiovascular endpoints by 32% 
(P < 0.001). Total mortality was reduced by 26% (P = 0.05), 
but a similar reduction in cardiovascular mortality did not 
reach statistical significance in this analysis. Compared with 
placebo, active treatment also reduced the incidence of 
dementia by 50%. 
Conclusion. Stepwise antihypertensive drug treatment, 
starting with the dihydropiridine calcium-channel blocker 
nitrendipine, improves prognosis in elderly patients with 
isolated systolic hypertension. 
S Afr Med f 2001; 91: 1060-1068. 
. By 1988 several major outcome trials on antihypertensive drug 
treatment had been published.1•5 However, at that time the 
findings in the elderly still left a wide margin of uncertainty, as 
evidenced by the borderline significance of the effects of 
therapy on fatal endpoints.' Indeed, the results of the early 
trials1•5 demonstrated that antihypertensive drug treatment 
reduced all cardiovascular deaths by 28% (P = 0.02) and stroke 
mortality by 41 % (P = 0.03), while the decreases in coronary 
(-28%, P = 0.14) and all-cause mortality (-14%, P = 0.07) had 
not reached statistical significance. 6 Furthermore, until 1988, all 
outcome trials in hypertension had used diastolic blood 
pressure (DBP) as the main criterion to recruit patients and to 
adjust treatment. This was in contrast to the growing insight 
gained from many cross-sectional and longitudinal studies that 
in older patients systolic blood pressure (SBP) is an important 
cardiovascular risk factor, whereas DBP is not associated - or 
may even be inversely correlated - with cardiovascular 
outcome.7 In addition, the prevalence of isolated systolic 
hypertension rises curvilinearly with age. It averages 8% in 
sexagenarians and exceeds 25% beyond 80 years.7 Thus, 
isolated systolic hypertension affects a considerable proportion 
of all older subjects. 
Against this background, in 1989, the European Working 
Party on High Blood Pressure in the Elderly started the 
placebo-controlled double-blind Syst-Eur (Systolic 
Hypertension in Europe) Trial.' Active treatment was initiated 
with the dihydropyridine calcium-channel blocker 
nitrendipine,' with the possible addition of enalapril, hydro-
chlorothiazide or both drugs. In 1991 the Systolic Hypertension 
in the Elderly (SHEP) Trial1° demonstrated that diuretic-based 
treatment prevented non-fatal stroke, myocardial infarction 
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(MI) and congestive heart failure (CHF). In view of the 
remaining uncertainties with regard to the treatment of isolated 
systolic hypertension in the elderly,11-15 the Syst-Eur Trial 
continued after the publication of the SHEP results.10 
Furthermore, the controversy over the role of calcium-channel 
blockers as first-line antihypertensive agents"·19 highlighted the 
lack of evidence that these drugs also reduce cardiovascular 
risk. 
The primary hypothesis tested was that in older patients 
with isolated systolic hypertension, active treatment could 
reduce fatal and non-fatal stroke. The secondary endpoints 
included total and cardiovascular mortality, all cardiovascular 
endpoints and fatal and non-fatal cardiac endpoints. This 
review article reports the morbidity and mortality results for 
the 4 695 randomised Syst-Eur patients. The trial stopped on 
14 February 1997 after the second of four planned interim 
analyses. According to the predefined stopping rules, a 
significant benefit for stroke, the primary endpoint of the trial,' 
had been reached. 
PATIENTS AND METHODS 
The protocol of the multicentre Syst-Eur Trial' was approved 
by the Ethics Committees of the University of Leuven and the 
participating centres. The trial was conducted according to the 
principles outlined in the Helsinki Declaration.2° 
Patients were recruited from 198 centres in 23 countries 
across western and eastern Europe. Each centre kept a register 
of screened patients. Patients were eligible: (i) if they were at 
least 60 years old; (ii) if on single-blind placebo treatment 
during the run-in phase their sitting SBP ranged from 160 to 
219 mmHg, with DBP below 95 mmHg; (iii) if their standing 
SBP was 140 mmHg or more; (iv) if they consented to be 
enrolled; and (v) if long-term follow-up was possible. The BP 
criteria for entry were based on the average of 6 sitting and 6 
standing readings, i.e. 2 in each position at 3 baseline visits 1 
month apart. Patients could not be enrolled if the systolic 
hypertension was secondary to a condition for which specific 
medical or surgical treatment was indicated. The other 
exclusion criteria included retinal haemorrhage or 
papilloedema; CHF; dissecting aortic aneurysm; a serum 
creatinine concentration at presentation of 180 µmol/l 
(2 mg/ dl) or higher; a history of severe nose bleeds, stroke or 
MI within 1 year of randomisation; dementia or substance 
abuse; any condition prohibiting a sitting or standing position; 
and any severe concomitant cardiovascular or non-
cardiovascular disease. 
Eligible patients were stratified by centre, sex and previous 
cardiovascular complications and randomised to double-blind 
treatment with active medication or placebo. Active treatment 
was initiated with nitrendipine (10 - 40 mg/ day). If necessary, 
the calcium-channel blocker was combined with or replaced by 
enalapril (5 - 20 mg/day) or hydrochlorothiazide 
(12.5 - 25 mg/ day) or both drugs. The study medications were 
stepwise titrated and combined in an attempt to reduce the 
sitting SBP by 20 mmHg or more to less than 150 mmHg.• 
To facilitate the intention-to-treat analysis, patients 
withdrawing from double-blind treatment were maintained in 
open follow-up.• For patients withdrawing from double-blind 
treatment, and for whom regular follow-up was impossible, 
information on vital status, the incidence of major endpoints 
and other events and the use of antihypertensive medications 
were collected annually (non-supervised open follow-up). 
MORBIDITY AND MORTALITY RESULTS IN THE 
INTENTION-TO-TREAT ANALYSIS21" 2 
At randomisation the patients in the placebo (N = 2 297) and 
active-treatment (N = 2 398) groups had similar characteristics 
(Table I). In the intention-to-treat analysis the median follow-
up of the 4 695 patients was 2.0 years. At 2 years, nitrendipine 
or matching placebo was the only treatment administered to 
597 (58.9%) and 343 (39.6%) patients, respectively. Among the 
patients in open follow-up at 2 years, 65 (36.5%) of those 
randomised to active treatment and 157 (58.1 %) of those in the 
placebo group were on antihypertensive drugs, while 
treatment status with regard to hypertension was 
undocumented in 88 (49.4%) and 81 (30.0%) patients, 
respectively. The between-group differences in the sitting BP 
averaged 10.1/4.5 mmHg (95% confidence interval (CI) 8.8 -
11.4/3.9 - 5.1 mmHg) at 2 years and 10.7 /4.7 mmHg (CI 8.8 -
12.5/3.7 - 5.6 mmHg) at 4 years. The differences in heart rate 
were -0.1 beats per minute (Cl-0.8 - 0.6 beats/min) and -06 
beats/min (Cl - 1.7 - 0.5 beats/min), respectively. 
Cardiovascular mortality tended to be lower on active 
treatment (-27%, CI -48 - 2%, P = 0.07), but all-cause mortality 
was not significantly changed (-14%, Cl-33 - 0%, P = 0.22). 
Fatal or non-fatal stroke was observed in 77 patients 
randomised to placebo and in 47 of the active-treatment group. 
The cumulative rates were 13.7 and 7.9 strokes per 1 000 
patient-years (Table II). Active treatment reduced the 
occurrence of total stroke by 42% (P = 0.003) and that of non-
fatal stroke by 44% (P = 0.007). In the active-treatment group, 
non-fatal cardiac endpoints decreased by 33% (P = 0.03). All 
fatal and non-fatal cardiac endpoints, including sudden death, 
declined by 26% (P = 0.03). A similar trend was observed for 
non-fatal heart failure (-36%, P = 0.06), for all cases of heart 
failure (-29%, P = 0.12) and for fatal and non-fatal MI (-30%, 
P = 0.12, Table II). Active treatment reduced all fatal and non- IDIIJ 
fatal cardiovascular endpoints by 31 % (P < 0.001). The 
incidence of fatal and non-fatal cancer (-15%, CI -38 - 16%, 
P = 0.29) and bleed_ing (not including cerebral and retinal 
haemorrhages) (-10%, CI -52 - 69%, P = 0.74), was similar in 
the two treatment groups. In terms of absolute benefit, at the 
rates observed in the placebo group, treating 1 000 elderly 
mifl 
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patients with isolated systolic hypertension for 5 years could 
prevent 29 strokes or 53 major cardiovascular events. 
After the publication of the main outcome results on 13 
September 1997,21 efforts to locate all patients continued and 
the database was updated.22 The number of patients lost to 
follow-up decreased from 116 to 61 (2.7%) in the placebo group 
Table I. Clinical features of the treatment groups at randomisation 
Characteristic 
Age in years (mean (SD)) 
BP in mmHg (mean (SD)) 
Sitting SBP (mmHg) 
Sitting DBP (mmHg) 
Standing SBP (mmHg) 
Standing DBP (mmHg) 
Sitting heart rate, beats/min (mean (SD)) 
Body mass index, kg/m2 (mean (SD)) 
Men 
Women 
Serum cholesterol, mmol/l (mean (SD)) 
Total cholesterol 
High-density lipoprotein cholesterol 
Characteristic present at baseline (N (%)) 
Female 






Abstaining from alcohol 
Drinking < 1 unit alcohol per day 
Drinking ;:: 1 unit alcohol per day 
* Defined according to the criteria of the World Health Organisation." 
and from 121 to 63 (2.6%) in the active-treatment group; the 
number of patient-years accumulated increased from 5 709 to 
5 844 and from 5 995 to 6 140, respectively. However, the 
slightly greater number of endpoints available for analysis" did 
not affect the conclusions of the initial Syst-Eur report. 21 
Placebo 











1 520 (66.2%) 
1 083 (47.1 %) 
697 (30.3%) 
240 (10.4%) 
1 705 (74.2%) 
427 (18.6%) 
164 (7.1 %) 















1 618 (67.5%) 
1 104 (46.0%) 
705 (29.4%) 
252 (10.5) 
1 763 (73.5%) 
454 (18.9%) 
179 (7.5%) 
1 724 (71.9%) 
414 (17.3%) 
258 (10.8%) 
SD = standard deviation, BP = blood pressure, SBP = systolic blood pressure, DBP = diastolic blood pressure. 
Table II. Non-fatal endpoints alone and combined with fatal endpoints 













All cardiovascular endpoints 
Rate per 1 000 patient-years 
(number of endpoints) 
Placebo Active 
(N= 2297) (N = 2 398) 
10.1 (57) 5.7 (34) 
0.0 (0) 0.2 (1) 
12.6 (70) 8.5 (50) 
7.6 (43) 4.9 (29) 
5.5 (31) 4.4 (26) 
0.4 (2) 0.5 (3) 
13.7 (77) 7.9 (47) 
20.5 (114) 15.1 (89) 
8.7 (49) 6.2 (37) 
8.0 (45) 5.5 (33) 
33.9 (186) 23.3 (137) 
Relative difference with 
rate in placebo group 
% rate 
(95% Cl) p 
-44 (-63, -14) 0.007 
-33 (-53, -3) 0,03 
-36 (-60, 2) 0.06 
-20 (-53, 34) 0.40 
-42 (-60,-17) 0.003 
-26 (-44, -3) 0,03 
-29 (-53, 10) 0.12 
-30 (-56, 9) 0.12 
-31 (-45, -14) < 0.001 
*Non-fatal and fatal cardiac endpoints included fatal and non-fatal heart failure, fatal and non-fatal myocardial infarction and sudden death. 
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SUBGROUP ANALYSIS ACCORDING TO 
TREATMENT INTENTION23 
In the intention-to-treat analysis, male sex and cardiovascular 
complications were positively and independently correlated 
with cardiovascular risk, but the relative risk reduction was 
similar in men and women and was not influenced by the 
presence of cardiovascular complications at entry. In multiple 
Cox regression analysis, the P-values for the interactions with 
treatment ranged from 0.62 to 0.86 for sex and from 0.26 to 0.87 
for cardiovascular complications. 
Age was a strong predictor of outcome. In Cox regression 
with adjustment applied for significant covariates, the 
treatment-by-age interaction term was significant (P == 0.009) 
for total mortality and nearly significant (P = 0.09) for 
cardiovascular mortality, indicating that the benefit of 
treatment was lost after the age of about 75 years. In contrast, 
the treatment-by-age interaction terms for the combined fatal 
and non-fatal events were not statistically significant. Similar 
analyses revealed that the effect of treatment on total mortality 
was more prominent at higher initial SBP (P = 0.05), but this 
was not the case for combined endpoints. 
At randomisation, the median daily use of tobacco was 15 
cigarettes in 231 male smokers (P5 - P95 interval (Pl) 3 - 50 
cigarettes) and 10 cigarettes (PI 2 - 30 cigarettes) in 112 female 
smokers. Both before and after adjustment for significant 
covariates, smoking predicted total and cardiovascular 
mortality and the combined fatal and non-fatal cardiovascular 
and cardiac endpoints. With adjustments applied for significant 
covariates, Cox regression for stroke showed a significant 
interaction (P = 0.01) between treatment and smoking. The 
relative hazard rate of active versus placebo treatment was 0.47 
(CI 0.32 - 0.69) in non-smokers, but 2.75 
(CI 0.73 - 10.4) in smokers. At randomisation, 393 men and 132 
women consumed at least one unit of an alcoholic beverage per 
day, i.e. one glass of beer, wine, aperitif, fortified wine or 
liquor. Their median daily consumption of alcohol was 19 g (PI 
10 - 54 g) and 14 g (PI 10 - 36 g), respectively. Alcohol intake at 
entry and the alcohol-by-treatment interaction terms were not 
correlated with outcome before or after adjustment for 
covariates. 
Of the 4 695 patients, 1 994 (42.5%) had been recruited in 
eastern Europe. However, because of the longer follow-up of 
the western European patients (median 3.4 versus 1.1 years), 
approximately 75% of the endpoints were noticed in western 
Europeans. In terms of relative risk reduction, the outcome 
results were similar in eastern and western European patients. 
PER-PROTOCOL ANALYSIS 
In the per-protocol analysis, i.e. the analysis of the patients on 
double-blind medication, the number of patient-years in the 
placebo and active treatment groups amounted to 4 508 and 
5 166, respectively (83% of the total number of patient-years). 
Median follow-up was 1.7 years. The between-group 
differences in the sitting SBP and DBP then averaged 
11.6 mmHg and 5.3 mmHg, respectively. In the patients 
remaining on double-blind medication, active treatment 
significantly reduced total mortality by 26% (P == 0.05). Similar 
though non-significant trends were observed for cardiac (-20%, 
P == 0.34) and cerebrovascular (-31 %, P == 0.36) mortality. 
The per-protocol analysis of the combined fatal and non-fatal 
endpoints produced results similar to those in the intention-to-
treat approach. Active treatment reduced cardiovascular, 
cardiac and cerebrovascular events by 32% (P < 0.001), 26% 
(P = 0.05) and 44% (P = 0.004), respectively. In terms of 
absolute benefit, the per-protocol analysis suggested that 
treating 1 000 patients for 5 years would prevent 24 deaths, 29 
strokes, 25 cardiac endpoints or 54 major cardiovascular events. 
In general, the results were remarkably similar in the intention-
to-treat and per-protocol analyses. 
CALCIUM-CHANNEL BLOCKADE AND 
CARDIOVASCULAR PROGNOSIS2• 
In the Syst-Eur Trial, active treatment was initiated with the 
dihydropyridine calcium-channel blocker nitrendipine.' The 
controversy about possible adverse effects of calcium-channel 
blockers arose only in 199518 and was not considered in 1991 or 
1992, when the Ethics Committee of the Syst-Eur Trial and the 
review boards of the participating centres decided to continue 
the trial. However, in view of the persistent concerns about the 
use of calcium-channel blockers as first-line antihypertensive 
drugs,1'·1'"5-29 further analyses addressed the question whether 
treatment with nitrendipine' alone could influence prognosis. 
At 6 months, 1 517 patients of the placebo group (66.0%) and 
1 829 of those randomised to active treatment (76.3%) were still 
on monotherapy with the first-line study medication. The net 
BP reduction in the active-treatment group was 7.7 mmHg SBP 
and 3.3 mmHg DBP. At this early moment in the trial, when 
most patients were still on the first-line medication, active 
treatment reduced all cardiovascular endpoints by 55% (CI 20 -
75%, P = 0.005), all cardiac endpoints by 62% (CI 21 - 82%, 
P = 0.007), total mortality by 60% (CI 17 - 81 %, P = 0.01) and 
cardiovascular mortality by 62% (CI 14 - 83%, P == 0.02). In 
contrast, the 37% (CI -78 - 77%) reduction in fatal and non-fatal 
stroke was not yet significant. The relative reduction in all 
cardiovascular endpoints at 6 months was of the same order of 
magnitude as at 1, 2, or 4 years of follow-up, when more 
patients had proceeded to combined therapy (Fig. 1). IDI'I] 
To ascertain that the apparent benefit conferred by 
nitrendipine was not due to selection bias in the control group, 
the 1 327 patients who remained on single nitrendipine 
treatment throughout the entire trial were matched by sex, age 
(60 - 69, 70 - 79, and~ 80 years), previous cardiovascular 
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1 (P 0.001) 
l 
- -- • - - - Placebo (N= 2 297) 
--- Active treatment (N = 2 398) 
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Time since.randomisation (yrs) 
Fig. 1. Cumulative rates of all cardiovascular endpoints in the per-
protocol analysis. The between-group differences in the rates are 
presented for various follow-up intervals. The benefit of active 
treatment was already significant at 6 months, when most of the 
4 695 randomised patients were still on monotherapy with active 
nitrendipine or matching placebo. (From reference 24, with 
permission.) 
number of placebo patients drawn from the control group, 
regardless of the type of the placebos taken. At 2 years (median 
follow-up in the two groups), the net BP reduction in the 
actively treated patients averaged 13.7 mmHg SBP and 5.4 
mmHg DBP. Compared with the matched control group, active 
nitrendipine reduced cardiovascular mortality by 41 % 
(P = 0.05), all cardiovascular endpoints by 33% (P = 0.01), fatal 
and non-fatal cardiac endpoints by 33% (P = 0.05), and fatal 
and non-fatal heart failure by 48% (P = 0.05). 
OUTCOME IN DIABETIC AND NON-DIABETIC 
PATIENTS'0 
At randomisation, 492 patients (10.5%) had diabetes mellitus 
according to the criteria of the World Health Organisation" 
(Table I). At 2 years (median follow-up), the net differences in 
BP between the placebo and active-treatment groups were 
8.6 mmHg SBP and 3.8 mmHg DBP in the diabetic patients; in 
the 4 203 patients without diabetes, these differences were 
10.3 mmHg and 4.6 mmHg, respectively. 
In the survival analysis without adjustment for possible 
confounders, active treatment in the diabetic patients reduced 
the incidence of total mortality (-41 %, CI-69 - 9%, P = 0.09), 
cardiovascular mortality (-70%, CI-89 - -19%, P = 0,01), all 
cardiovascular endpoints (-62%, CI -80 - -19%, P = 0.002), 
fatal and non-fatal stroke (-69%, CI-89 - -14%, P = 0.02) and 
cardiac endpoints (-57%, CI -82 - 6%, P = 0.06). In the non-
diabetic patients, treatment only decreased the risk of all 
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cardiovascular complications (-25%, CI -41 - 5%, P = 0.02) and 
stroke (-36%, CI -57 - -5%, P = 0.02). 
In diabetic patients (Fig. 2), with adjustments for possible 
confounders applied, active treatment reduced all-cause 
mortality by 55%, cardiovascular mortality by 76%, all 
cardiovascular endpoints by 69%, fatal and non-fatal stroke by 
73% and all cardiac endpoints by 63%. In the non-diabetic 
patients, active treatment decreased all cardiovascular 
endpoints by 26% and fatal and non-fatal stroke by 38%. Active 
treatment reduced total mortality (P = 0.04), cardiovascular 
mortality (P = 0.02) and all cardiovascular endpoints (P = 0.01) 
significantly more in diabetic than in non-diabetic patients.30 
Effects of antihypertensive treatment 
Diabetics Non-diabetics 
(N= 492) (N=4203) 
Mortality 0,45 
total o::=J P'=0.04 
0,24 
Cardiovascular rr=::J P=0.02 
Fatal and non-fatal endpoints 0.31 
Cardiovascular IIJ P=0,01 
0.27 
Stroke [J:=J P=0,13 
0,37 
Cardiac I I P=0.12 
-Active better 
0 0.5 1.0 0,25 0.5 1,0 1,5 2.0 
Relative hazard rates (adjusted) 
* For treatment-by-diabetes interaction. 
Fig. 2. Relative hazard rates of active treatment versus placebo in 
diabetic and non-diabetic patients with cumulative adjustments for 
sex, age, previous cardiovascular complications, systolic blood 
pressure at entry, smoking, and residence in western Europe. The P-
values refer to the treatment-by-diabetes interaction and indicate 
whether the treatment effect was significantly different according to 
the presence of diabetes at randomisation. (From reference 30, with 
permission.) 
PREVENTION OF DEMENTIA'"" 
Systolic hypertension increases the risk of dementia in ageing 
people. The Vascular Dementia Project,'"34 set up in the 
framework of the Syst-Eur Trial, investigated whether 
antihypertensive drug treatment could reduce the incidence of 
dementia. At baseline and follow-up, cognitive function was 
assessed by the Mini Mental State Examination (MMSE).35 If the 
MMSE score was 23 or less, then the diagnosis of dementia 
was ascertained based on the DSM-III-R criteria.36 In dementia 
cases the Modified Ischaemic Score,37 including a computerised 
tomography (CT) brain scan, served to differentiate vascular 
from degenerative disease. If a brain scan could not be 
performed, then the Hachinski Score" replaced the Modified 
Ischaemic Score37 to establish the cause of dementia. 
In total, 2 418 patients were enrolled in the dementia study. 
Median follow-up in the intention-to-treat analysis was 2.0 
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-60% (2 - 83%) 
P= 0.03 
Fig. 3. Incidence of dementia by treatment group in the intention-to-
treat and per-protocol analyses. 
years. Compared with placebo (N = 1 180), active treatment 
(N == 1 238) reduced the incidence of dementia by 50% (CI -76 -
0%, P = 0.05) from 7.7 tor3.8 cases per 1 000 patient-years 
(Fig. 3). In the per-protocol analysis, active treatment decreased 
the rate by 60% (CI -83 - - 2%, P = 0.03). Active treatment 
prevented mainly degenerative dementia (8 v. 15 cases in the 
intention-to-treat analysis), but also vascular (0 v. 2) and mixed 
(3 v. 4) dementias. At the risk observed in the placebo group , 
treating 1 000 hypertensive patients for 5 years could prevent 
19 cases of dementia. 
PROGNOSTIC VALUE OF CONVENTIONAL AND 
AMBULATORY BLOOD PRESSURE'._.' 
Within the framework of the Syst-Eur Trial, the Study on 
Ambulatory Blood Pressure Monitoring was set up to compare 
the prognostic accuracy of conventional and ambulatory BP 
measurements.3941 Follow-up of the placebo group also made it 
possible to validate proposed diagnostic thresholds42"'' for BP 
monitoring in terms of morbidity and mortality. Of 198 Syst-
Eur centres, 46 opted to enrol their patients. 
Interim reports on the Study on Ambulatory Blood Pressure 
Monitoring showed: (i) that the daytime SBP decreased by 
2 - 3 mmHg on lo:µg-term placebo .treatment;43•44 (ii) that in 
parallel-group trials or in clinical experiments focusing on the 
BP profile during the whole day, ambulatory BP monitoring 
does not allow for economising on sample size;" and (iii) that it 
is possible to calculate the trough-to-peak ratio in parallel-
group trials while fully accounting for placebo effects as well as 
interindividual variability.46 
In the main analysis of the Study on Ambulatory Blood 
Pressure Monitoring,41 29 (3.5%) of 837 randomised patients 
with a 24-hour BP recording at baseline, were excluded because 
less than 80% of the required readings were available. SBP and 
DBP were on average 22.0 mmHg and 2.0 mmHg higher (P < 
0.001) on conventional than on daytime (from lOhOO to 20h00)47 
ambulatory measurement. 
With cumulative adjustments applied for sex, age, previous 
cardiovascular complications, smoking and residence in 
western Europe,23 a higher SBP at randomisation predicted a 
worse prognosis (Fig. 4), whereas the association between DBP 
and outcome was not significant. In the placebo group 
(N = 393), the 24-hour, daytime and nighttime (from midnight 
to 06hOO) systolic ambulatory BPs predicted the incidence of 
cardiovascular complications even after further adjustment for 
the conventional BP. The nighttime SBP behaved as a more 
accurate predictor of endpoints than the daytime level (except 
for stroke). The 24-hour level and the night-to-day ratio of SBP 
were significantly and independently correlated with the 
incidence of all cardiovascular endpoints in the placebo group. 
The relative hazard rates associated with a 10 mmHg increase 
in the 24-hour BP and with a 10% higher night-to-day ratio 
were 1.23 (CI 1.03 - 1.46, P = 0.02) and 1.41 (CI 1.03 -1.94, 
P = 0.03), respectively. In the placebo group, the cardiovascular 
risk conferred by a conventional SBP of 160 mmHg at 
randomisation was similar to those associated with a 24-hour, 
daytime or nighttime SBP of 142 mmHg, 145 mmHg or 
132 mmHg, respectively. In the active-treatment group 
(N = 415), SBP at randomisation did not significantly predict 
cardiovascular risk, regardless of the technique of BP 
measurement. This again confirmed that nitrendipine-based 
treatment substantially reduced the excess risk conferred by the 
increased SBP at randomisation. 
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Fig. 4. Systolic blood pressure on conventional, 24-hour, daytime, 
and nighttime measurement at randomisation as predictors of the 2-
year incidence of cardiovascular endpoints in the placebo group. The 
Cox models were standardised to female sex, 69.6 years (mean age), 
no previous cardiovascular complications, non-smoking and 
residence in western Europe. (From reference 41, with permission,) 
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DISCUSSION 
Stepwise antihypertensive drug treatment in the Syst-Eur Trial 
consisted of the dihydropyridine calcium-channel blocker 
nitrendipine, the converting-enzyme inhibitor enalapril and the 
thiazide diuretic hydrochlorothiazide. In elderly patients with 
isolated systolic hypertension, these drugs reduced the risk of 
stroke, the primary endpoint in the Syst-Eur Trial, as well as 
the incidence of various other cardiovascular complications 
and dementia. 
Syst-Eur, a trial in isolated systolic hypertension 
The benefits of antihypertensive treatment in the Syst-Eur 
study were, in relative terms, similar to those in six other 
trials'·'"·5•48"' in older patients with combined systolic and 
diastolic hypertension. Overall, in these studies, antihyper-
tensive treatment reduced fatal stroke by 33% and cardio-
vascular mortality by 22%.50 In a subsequent quantitative 
review,51 which also included the SHEP Trial,10 but not the small 
Japanese study by Kuramoto,' these pooled estimates were also 
the same, i.e. 33% and 22%. In the intention-to-treat analysis, 
the Syst-Eur results with regard to the number of prevented 
strokes were in close agreement with those reported by the 
SHEP investigators. 10 In relative terms the percentage reduction 
in stroke incidence amounted to 42% and 36%,10 respectively, 
while in both trials approximately 35 patients had to be treated 
for 5 years to prevent one stroke. For cardiovascular mortality, 
the relative benefit in the intention-to-treat analysis amounted 
to 27% and 20%,10 respectively, while 5 000 patient-years of 
treatment prevented 18 and lOcardiovascular deaths. 10 
Syst-Eur as a calcium-channel blocker trial 
Shortly after the first publication of the morbidity and 
mortality results of the Syst-Eur Trial, the question arose 
whether the observed beneficial effects of active treatment 
could be ascribed to any of the drugs used in this trial. Further 
analyses suggested that the dihydropyridine calcium-channel 
blocker nitrendipine, independent of the other associated 
antihypertensive drugs, prevented cardiovascular 
complications in older patients with isolated systolic 
hypertension. 24 
Several studies'2·54 investigated the effects of dihydropyridine 
calcium-channel blockers in Chinese hypertensive patients. The 
Shanghai Trial of Nifedipine in the Elderly (STONE) was a 
single-blind trial, in which 1 797 patients were alternatingly 
assigned to nifedipine (10 - 60 mg/ day) or placebo with the 
possible addition in both treatment groups of active captopril 
(20 - 50 mg/ day) or hydrochlorothiazide (25 mg/ day).53 
Patients whose DBP exceeded 110 mmHg were re-allocated to 
nifedipine. A total of 165 patients were excluded from analysis, 
but all endpoints were blindly assessed. In an intention-to-treat 
analysis, total stroke incidence decreased by 57% (CI -23 -
-763). In the nifedipine group, total mortality tended to 
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decline by 45% (CI -71 - 33). No significant changes were 
observed in cardiovascular mortality (-26%, CI -66 - 62%) and 
in the incidence of fatal and non-fatal MI (-63, CI -87 - 566%) 
and cancer (-763, CI -95 - 13%).53 The Syst-China Trial was a 
placebo-controlled study in older (2': 60 years) Chinese patients 
with isolated systolic hypertension.5456 The first-line 
antihypertensive agent in this study was also nitrendipine (10 -
40 mg/ day), with the possible addition of captopril (12.5 -
50 mg/ day) and hydrochlorothiazide (12.5 - 50 mg/ day). At 
entry the sitting BP averaged 171 mmHg SBP and 86 mmHg 
DBP, age averaged 66.5 years, and total serum cholesterol was 
5.1 mmol/l. At 2 years of follow-up, the between-group 
differences in BP were 9.1 mmHg SBP and 3.2 mmHg DBP. 
Active treatment reduced total stroke by 37% (CI 14 - 53%, 
P = 0.01), all-cause mortality by 39% (CI 16 - 57%, P = 0.003), 
cardiovascular mortality by 39% (CI 4 - 61 %, P = 0.03), stroke 
mortality by 58% (CI 14 - 80%, P = 0.02), and all fatal and non-
fatal cardiovascular endpoints by 37% (CI 14 - 53%, P = 0.004).54 
The Syst-Eur Trial invalidated the circumstantial evidence,16-1'·2w 61 
initially raised by a meta-analysis and several purely 
observational studies, for potentially dangerous side-effects of 
calcium-channel blockers. These observational reports1'·1'·'' left a 
large margin of uncertainty. With regard to MI, confounding by 
indication could not be excluded. One report1' associating the 
use of calcium-channel blockers with cancer was based on 47 
exposed cases spread over a wide variety of cancer sites and 
only provided information on exposure to calcium-channel 
blockers at baseline. In the same cohort, patients taking 
calcium-channel blockers were more likely to be on treatment 
with warfarin (6.0% v. 2.6%, P < 0.001) or aspirin (37.3% v. 
29.7%, P < 0.001),17 which may have confounded the issue of 
gastrointestinal bleeding. 1' 
Recently, the controversy over the use of calcium-channel 
blockers found new life in a series of articles29•5861 and 
comments" suggesting that calcium-channel blockers, 
including second-generation dihydropyridines such as 
amlodipine58 or nisoldipine,29 might be harmful, particularly in 
hypertensive patients with diabetes mellitus. The Syst-Eur Trial 
is the first double-blind placebo-controlled outcome study to 
prove that antihypertensive treatment starting with a 
dihydropyridine calcium-channel blocker is particularly 
beneficial in diabetic patients.30•63 Cardiovascular benefit was 
observed equally in the patients remaining on monotherapy 
with nitrendipine and in those progressing to combined 
treatment with nitrendipine plus enalapril, hydrochloro-
thiazide, or both drugs.30•63 
Prevention of dementia 
In older patients with isolated systolic hypertension, active 
treatment starting with the dihydropyridine calcium-channel 
blocker nitrendipine halved the rate of dementia from 7.7 to 3.8 
cases per 1 000 patient-years.33 
0H.IGINAL ARTICLES 
The primary hypothesis tested in the Syst-Eur project on 
cognitive function was that a reduction in BP would protect 
against vascular dementia.32 The prevention of Alzheimer's 
disease was unexpected, although recent studies indicate that 
vascular factors, particularly hypertension, may play a role in 
the development of degenerative dementias as well as vascular 
dementia proper.64 On the other hand, the observation that 
antihypertensive treatment with a thiazide did not protect 
against cognitive impairment in the SHEP Trial1° argues against 
the prevention of dementia by just lowering the BP. In vascular 
and degenerative dementias the calcium-channel blocker 
nimodipine, compared with placebo, slightly improved the 
MMSE scores.65 Thus, an additional or alternative explanation, 
albeit still unproven, could involve specific neuroprotection 
conferred by calcium-channel blockade.65·67 Indeed, the ageing 
brain loses its ability to regulate intracellular calcium, leading 
to a cascade of cellular impairments and, ultimately, to cell 
death.66' 68 The hypothesis of a possible central nervous action of 
nitrendipine is also supported by the observation that this drug 
crosses the blood-brain barrier and reduces the turnover of 
monoamine neuro-transmitters,69 many of which are deficient 
in degenerative dementias.67 Nitrendipine-binding in the rat 
brain also occurs mainly at those sites primarily affected by 
Alzheimer's disease, such as the superficial cortex, thalamus 
and hippocampus, and not in areas with low synaptic density.'° 
The potential reduction by 50% of the incidence of dementias 
by antihypertensive drug treatment initiated with the 
dihydropyridine calcium-channel blocker nitrendipine may 
have important public health implications in view of the 
increasing longevity of populations worldwide. At the rate 
observed in the placebo group, treating 1 000 hypertensive 
patients for 5 years could prevent 19 cases, a benefit which 
could even be larger in unselected higher risk groups. This 
beneficial outcome is in addition to the 53 major cardiovascular 
endpoints similarly prevented by the active drugs used in the 
Syst-Eur Trial.21 
CONCLUSIONS 
In summing up the Syst-Eur Trial, four conclusions emerge. 
First, this trial confirmed the SHEP findings10 that 
antihypertensive treatment of older patients with isolated 
systolic hypertension prevents or postpones cerebrovascular 
and other cardiovascular complications.'1'23 Second, the newer 
antihypertensive drug classes, exemplified by the calcium-
channel blocker nitrendipine, with the possible addition of 
enalapril, are at least equipotent to conventional drugs and 
may well serve as substitutes for the prevention of 
cardiovascular complications.24'63 Third, long-acting 
dihydropyridine calcium-channel blockers may be particularly 
indicated in patients with isolated systolic hypertension who 
also have diabetes mellitus'° or who are at risk of dementia." 
Finally, the circumstantial evidence1'·19,29,srn for potentially 
dangerous side-effects of calcium-channel blockers has not 
been borne out when put to the more rigorous test of a double-
blind placebo-controlled prospective trial with a median 
follow-up of 2 years, 
The Syst-Eur Trial, initiated by Antoon Amery (died on 
2 November 1994), was a concerted action of the European 
Community's Medical and Health Research Programme. The trial 
was carried out in consultation with the World Health 
Organisation, the International Society of Hypertension, the 
European Society of Hypertension and the World Hypertension 
League. The trial was sponsored by Bayer AG (Wuppertal, 
Germany). The National Fund for Scientific Research (Brussels, 
Belgium) provided additional support Study medication was 
donated by Bayer AG and Merck Sharp and Dohme Inc (West 
Point, Pa., USA). 
The authors gratefully acknowledge the secretarial assistance of 
R Wolfs. 
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